It is clear to prior to my return last April, the company had lost its way.

So last year, Congress passed the Inflation Reduction Act, which finally gives HHS the authority to negotiate drug prices for a select number of high-priced brand-name drugs.

But we also cannot lose sight of the ways that drug companies continue to abuse our intellectual property laws to drive out competition.

More than three out of four new patent applications for pharmaceuticals are for existing drugs.

So drug companies use these tricks, and a lot of others, to keep their monopolies and keep pushing prices higher and higher and higher.

CMS should absolutely finalize this rule. But I want to argue here that CMS needs to go further and end these insurance industry scams.

I thank the ranking member for yielding me time. Mr. Chairman, I rise in opposition to the majority's polluters over people act, a massive handout to some of the world's most profitable and most powerful corporations. It is a Big Oil…

Since Medicare was established in 1965, it has not covered routine dental benefits.

Union busting is disgusting.

It seems to me the solution is clear. It is time to expand Medicare to cover dental care, something I have long supported.

It is clear to prior to my return last April, the company had lost its way.

Or we can spend nearly a trillion dollars in overpayments to insurance companies for crummy coverage that beneficiaries do not use.

Despite these wins, there is more that we need to do to reduce exorbitant drug prices for all Americans.

It seems to me the solution is clear. It is time to expand Medicare to cover dental care, something I have long supported.

Or we can spend nearly a trillion dollars in overpayments to insurance companies for crummy coverage that beneficiaries do not use.

Since Medicare was established in 1965, it has not covered routine dental benefits.

The name of the game is volume. The more volume a drug company has with a particular PBM, and the greater the drug company's market share, the better the potential deal that the drug company can offer as an inducement to disfavor rival…

CMS should absolutely finalize this rule. But I want to argue here that CMS needs to go further and end these insurance industry scams.